Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression.
von Euw EM, Barrio MM, Furman D, Levy EM, Bianchini M, Peguillet I, Lantz O, Vellice A, Kohan A, Chacón M, Yee C, Wainstok R, Mordoh J. von Euw EM, et al. Among authors: mordoh j. J Transl Med. 2008 Jan 25;6:6. doi: 10.1186/1479-5876-6-6. J Transl Med. 2008. PMID: 18221542 Free PMC article. Clinical Trial.
Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCRβ Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood.
Aris M, Bravo AI, Garcia Alvarez HM, Carri I, Podaza E, Blanco PA, Rotondaro C, Bentivegna S, Nielsen M, Barrio MM, Mordoh J. Aris M, et al. Among authors: mordoh j. Front Immunol. 2019 Sep 18;10:2213. doi: 10.3389/fimmu.2019.02213. eCollection 2019. Front Immunol. 2019. PMID: 31620131 Free PMC article.
Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.
Podaza E, Carri I, Aris M, von Euw E, Bravo AI, Blanco P, Ortiz Wilczyñski JM, Koile D, Yankilevich P, Nielsen M, Mordoh J, Barrio MM. Podaza E, et al. Among authors: mordoh j. Front Immunol. 2020 Jun 5;11:1147. doi: 10.3389/fimmu.2020.01147. eCollection 2020. Front Immunol. 2020. PMID: 32582212 Free PMC article. Clinical Trial.
An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases.
Mordoh A, Aris M, Carri I, Bravo AI, Podaza E, Pardo JCT, Cueto GR, Barrio MM, Mordoh J. Mordoh A, et al. Among authors: mordoh j. Front Immunol. 2022 Apr 1;13:842555. doi: 10.3389/fimmu.2022.842555. eCollection 2022. Front Immunol. 2022. PMID: 35432383 Free PMC article. Clinical Trial.
IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.
Roberti MP, Rocca YS, Amat M, Pampena MB, Loza J, Coló F, Fabiano V, Loza CM, Arriaga JM, Bianchini M, Barrio MM, Bravo AI, Domenichini E, Chacón R, Mordoh J, Levy EM. Roberti MP, et al. Among authors: mordoh j. Breast Cancer Res Treat. 2012 Dec;136(3):659-71. doi: 10.1007/s10549-012-2287-y. Epub 2012 Oct 14. Breast Cancer Res Treat. 2012. PMID: 23065032
146 results